Is Lexeo Therapeutics, Inc. (LXEO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.0% / 30% | 24.3% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 2.0% / 33% | 24.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 6.8% / 33% | 82.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 2.0% / 33% | 24.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 6.8% / 33% | 82.7% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -80.7% | |
| Return on Assets (ROA) | -44.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$81M |
| Free Cash Flow | -$82M |
| Total Debt | $10M |
| Debt-to-Equity | 7.0 |
| Current Ratio | 7.4 |
| Total Assets | $147M |
Price & Trading
| Last Close | $5.65 |
| 50-Day MA | $6.79 |
| 200-Day MA | $6.84 |
| Avg Volume | 988K |
| Beta | 1.8 |
|
52-Week Range
$1.45
| |
About Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Lexeo Therapeutics, Inc. (LXEO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Lexeo Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Lexeo Therapeutics, Inc.'s debt ratio?
Lexeo Therapeutics, Inc.'s debt ratio is 2.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.8%.
What are Lexeo Therapeutics, Inc.'s key financial metrics?
Lexeo Therapeutics, Inc. has a market capitalization of $399M. Return on equity stands at -80.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.